Clinical Study
Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer
Table 2
Responses based on clinical evaluations and protein marker evaluations at the end of therapy among the 29 patients.
| | Evaluation | Complete response (CR) | Partial response (PR) | No change (NC) | Progressive disease (PD) |
| | Clinical evaluation | 24% (7/29) | 14% (4/29) | 31% (9/29) | 31% (9/29) | | CA 15-3 evaluation | 14% (4/29) | 24% (7/29) | 48% (14/29) | 14% (4/29) | | CEA evaluation | 10% (3/29) | 17% (5/29) | 59% (17/29) | 14% (4/29) | | TPA evaluation | 14% (4/29) | 7% (2/29) | 55% (16/29) | 24% (7/29) |
|
|
